NEI Spring 2026: Psychiatry Enters Its Next Era

Across presentations and discussions with clinicians, researchers, and industry leaders, several themes consistently emerged. The field is no longer solely focused on symptom reduction, and conversations are becoming increasingly centered around identifying the right patient, the right mechanism, and the right timing for intervention.

Here are some of the biggest takeaways from this year's meeting:

Psychiatry Is Moving Toward More Individualized Treatment Strategies

One of the strongest themes throughout the meeting was the growing push toward precision medicine in psychiatry. Clinicians and researchers repeatedly discussed the need to better subtype major depressive disorder and other psychiatric conditions in order to improve treatment selection and outcomes.

The field is beginning to move beyond broad diagnostic categories and toward identifying biologically and clinically distinct patient populations. This was particularly evident in conversations around biomarkers, neuroplasticity, cognition, and treatment responsiveness.

Interest in biomarker-driven approaches continues to grow across psychiatry, particularly in areas involving treatment resistance, symptom stratification, and mood disorders such as postpartum depression. While psychiatry has long pursued the level of precision seen in fields such as oncology and neurology, there was clear momentum around making that vision increasingly achievable.

Treatment Resistance Remains One of Psychiatry's Greatest Challenges

Treatment-resistant depression and treatment-resistant anxiety remained central areas of focus throughout the meeting.

Speakers and key opinion leaders repeatedly highlighted the limitations of current treatment pathways and the need for therapies that work differently, work faster, and address symptoms unresolved by traditional approaches.

Importantly, there was also growing discussion around improving expectations for treatment response itself. Clinicians are increasingly questioning whether partial improvement should be considered acceptable when many patients continue to experience cognitive dysfunction, anhedonia, sleep disruption, metabolic burden, or persistent functional impairment.

The conversation is evolving from simply asking whether a treatment works to asking which patients it works for, what symptoms it meaningfully impacts, and how sustainably it improves quality of life.

Treatment Mechanisms to Watch

Several emerging treatment mechanisms generated significant interest across both academic and industry conversations.

Orexin Receptor Targeting

Orexin receptors were among the most consistently discussed targets. While these receptors were initially associated with narcolepsy and sleep disorders, clinicians now see additional potential applications in mood disorders, cognition, and disorders involving sleep dysregulation. Many believe this mechanism may become increasingly important in major depressive disorder, particularly in patients with prominent insomnia or fatigue-related symptoms.

Muscarinic Modulation

Interest in muscarinic approaches remains extremely high following recent advances in schizophrenia treatment. However, clinicians emphasized that the next generation of therapies will need to improve tolerability, ease of use, and patient adherence in order to achieve broader adoption.

Glutamatergic Neurotransmission

Novel approaches targeting glutamatergic signaling continue to generate excitement, particularly in major depressive disorder and agitation-related symptom domains. Recently approved glutamatergic therapies were repeatedly discussed as examples of how differentiated mechanisms can rapidly reshape expectations around efficacy and onset of action.

Psychedelics Without the Psychedelic Experience

One of the more nuanced discussions centered around psychedelics and neuroplasticity. While many clinicians remain optimistic about the potential of such treatments, there is increasing interest in next-generation compounds designed to promote neuroplasticity and rapid symptom response without requiring the hallucinogenic experience itself. The field appears increasingly focused on understanding which aspects of psychedelic therapies are truly driving clinical benefits.

The Need for Practical Scientific and Disease Education

Another theme that emerged consistently was the growing need for clinically relevant and practical disease state education.

As mechanisms become more complex and treatment pathways more individualized, clinicians are looking for deeper scientific engagement. Key opinion leader discussions highlighted a growing need for engagement that is practical, clinically relevant, and directly applicable to patient management and real-world treatment decisions.

The expectation is no longer just promotion—it is interpretation, translation, and guidance.

Where the Field Is Heading

Perhaps the clearest takeaway from the meeting is that psychiatry is entering a new phase of innovation with growing sophistication around nuanced mechanisms, patient subtypes, and more personalized approaches to treatment.

At the same time, the complexity of these conversations is increasing rapidly. Translating emerging science into meaningful clinical understanding, real-world adoption, and patient access will require stronger integration across medical affairs, education, market access, and strategic communication.

We at The HWP Group are excited to continue tracking where the field is heading and helping translate these emerging scientific conversations into actionable strategies for clients and stakeholders across disorders of the central nervous system.

Reported by The HWP Group's Katia Zalkind, PhD, ISMPP CMPP, and Sara Lemley